Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask The Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
FAQs
Advertising
PR Newswire
Report Store
UsernamePublicRestriction
Tags:
M & A Wound Healing & Tissue Repair Regenerative Medicine

Integra Adds ACell’s Regenerative Tech As It Dumps Extremity Orthopedics

  • News

Executive Summary

Integra will pay up to $400m for ACell to expand its wound management and soft-tissue repair product line. The deal is part of a larger restructuring plan that includes selling its orthopedics business.

You may also be interested in...



JPM 2021: Conformis Announces ACS Knee For 2H 2021, Integra Weathers Pandemic

The annual J.P. Morgan Healthcare Conference includes presentations from many major medtech companies outlining their growth strategies and expectations for 2021. Here are some of the highlights from the final day of the meeting.

JPM 2021: EY Says Pandemic Leaves Medtech With $500Bn In M&A Firepower

EY’s M&A Firepower report predicts very active M&A activity for medtechs in 2021, driven by diagnostics and digital health, but with some headwinds remaining.

New Trial Shows BENEFIT Of J&J/Auris’ Monarch Bronchoscopy Platform

New published results demonstrate J&J/Auris’ robotic is safe and effective at diagnosing peripheral pulmonary lesions.

Table

View full table

Topics

Related Companies

Tags:
M & A Wound Healing & Tissue Repair Regenerative Medicine
UsernamePublicRestriction

Register

PS051363

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By